Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727999 · ClinicalTrials.gov registry record
Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 75
- Enrollment target
NCT01727999: Completed study, sponsored by Stanford University.
NCT01727999 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01727999 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
Introduction: Ineffective platelet production has been proven to play a role in the etiology of Immune Thrombocytopenia (ITP) in addition to increased platelet destruction. The second-generation thrombopoietin (TPO) mimetics have shown good efficacy in boosting platelet counts in the great majority of patients with chronic ITP in several clinical trials.1, 2 Nevertheless, about 20% of patients with ITP fail to respond to the TPO mimetic treatment. Those treatment-resistant patients are un-characterized and the reasons for the lack of response have not been studied. The identification of predictive blood biomarkers of patients' response to treatment will be useful in reducing both cost and potential side effects; and it will be of equal importance and interest to investigate the molecular mechanisms underlying the patients' heterogeneous responses to TPO mimetic treatment. Specific Aims: 1. To identify blood classifier genes which correlate with patients' response to TPO mimetic treatment. 2. To compare the blood gene expression changes in responders and non-responders after TPO mimetic treatment and explore the possible molecular mechanisms accounting for the non-responsiveness to the treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2012-07 |
| Est. Completion | 2017-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01727999
The ClinicalTrials.gov registry entry for NCT01727999 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01727999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01727999 about?
NCT01727999 is a clinical study titled "Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics". Introduction: Ineffective platelet production has been proven to play a role in the etiology of Immune Thrombocytopenia (ITP) in addition to increased platelet destruction. The second-generation thrombopoietin (TPO) mimetics have shown good efficacy in boosting platelet counts in the great majority...
What is the current status of trial NCT01727999?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2012-07. Estimated completion is 2017-02.
Who is sponsoring clinical trial NCT01727999?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.